Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 8/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | FDPS | P14324 | 4/20 | 0.41 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12952597 | 0.98 | DNM1 (0.42) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL23823170 | 0.91 | DNM1 (0.59) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL18612349 | 0.91 | DNM1 (0.52) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL21025113 | 0.91 | DNM1 (0.50) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL21230005 | 0.91 | DNM1 (0.50) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL9605241 | 0.91 | DNM1 (0.38) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL20233395 | 0.91 | DNM1 (0.50) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL22921039 | 0.88 | DNM1 (0.48) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL5574361 | 0.88 | TSHR (0.47) | TSHRFDPSSMPD1THRBGGPS1 | |
| SCHEMBL4865538 | 0.88 | TSHR (0.47) | TSHRFDPSSMPD1THRBGGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210106690-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2021-04-15 | — | — | US | disclosed |
| US-10603386-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20170348424-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348424-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, CLTB, BRAP | DNM1 2053/4885TSHR 3548/4885MEN1 4707/4885 |
| US-20210106690-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, CLTB, BRAP | DNM1 1990/4885TSHR 3543/4885MEN1 4632/4885 |
| US-10603386-B2 | Protein-polymer-drug conjugates | PBRM1, CLTB, BRAP | DNM1 2040/4885TSHR 3559/4885MEN1 4621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.